Shaping a Brighter Future: AI’s impact on healthcare
Global Head of Corporate Affairs Sarah de Lagarde lost two limbs in a London Underground accident in 2022. Hear from her as she explains how AI is aiding her recovery, as well as from Portfolio Manager Andy Acker, who says Sarah’s story is emblematic of the many advances occurring in healthcare.
7 minute watch
Key takeaways:
- Although artificial intelligence (AI) will likely have a wide range of applications, the technology’s impact on healthcare could be felt globally.
- AI-enabled prosthetic limbs, for example, can now mimic fine motor functions, as explained by Sarah de Lagarde, who has used one since losing her right arm in a severe train accident.
- Such innovation is accelerating throughout the healthcare sector and creating a multitude of opportunities for both patients and investors.
IMPORTANT INFORMATION
Health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.
Technology industries can be significantly affected by obsolescence of existing technology, short product cycles, falling prices and profits, competition from new market entrants, and general economic conditions. A concentrated investment in a single industry could be more volatile than the performance of less concentrated investments and the market as a whole.
JHI
JHI
Andy Acker: The level of innovation that we’re seeing today in the healthcare sector is like nothing I would have imagined. I’ve been investing in the healthcare sector for almost 25 years at Janus Henderson, and the breakthroughs that we’re seeing today and the impact that they’re having on patients are just beyond imagining. Almost…a lot of what we’re doing today would have seemed like science fiction, even 10 years ago.
Michael Wooldridge: So, AI has a huge range of potential applications. It’s going to affect pretty much every, every aspect of our lives, every aspect of our working life, our leisure life. It will create endless new opportunities. But healthcare, I think, is one of the application areas where it’s going to be, has the potential at least to be transformative globally. AI in healthcare, I think, is the single most exciting application of this technology.
Sarah de Lagarde: At the end of 2022, I was involved in an unfortunate accident. As I was using public transport in London, I slipped on a wet and uneven platform and fell in between the gap, in between the stationary train and the platform, and nobody heard or saw me. The train departed, and I lost my right arm above the elbow and my right leg below the knee.
I was eventually found and rescued and then embarked on a long journey of rehabilitation. I was fitted with prosthetics; especially the arm prosthetic is an interesting piece of technology, as it is a state-of-the-art bionic arm that has an articulated elbow and a multi-articulated hand. It is a non-invasive piece of kit. It’s basically a custom-made socket that has about 16 electrodes embedded in that are fitted on the residual limb. It enables me to think about a gesture, I twitch the right combination of muscles inside the socket, the electrodes pick up the signal, and transform that into electric impulses that lead me to be able to move my bionic hand.
Simon Pollard: COVVI was formed back in July 2017, with a mission to deliver a world-leading prosthetic hand with users and clinicians at its heart. Working together, we wanted to actuate real positive change to the lives of people with upper-limb deficiency and give the end patient a real choice.
It has unrivaled or unmatched technology in its make-up. Our innovative remote-assist features – which basically means we can access the hand anywhere remotely in the world and help with configurations – help with set-up or any problems from a software issue. We then have a user-friendly app, which is there to help the amputees obviously go in and change any settings and reduce the mental and physical workload required to basically start up the hand. It has 24 programmable grips and gestures, which obviously facilitate fine motor skills and offer precise and versatile control over a wide range of finger movements.
Here we are today, with a hand which we believe is changing people’s lives on a day-to-day basis. Machine learning provides a personalized control. So, AI algorithms learn from your individual movements and patterns and preferences and allow the prosthetic to adapt and tailor its behavior.
de Lagarde: The artificial intelligence part inside the bionic arm is really interesting because it makes the users life so much easier. Every day I use the arm, data gets collected in how I use the arm, and that data sits in a central server, but it also sits inside an application that I have on my phone, and I can calibrate that every day. And every day the machine learns how I use those specific grip patterns, and, in essence, it makes it faster and easier for me to execute. So, a gesture that would have taken up a lot of brain power for me to activate, over time, it will go from 10 seconds to almost instantaneously, and that is super helpful for the end user.
Wooldridge: Where the technology is going, I say, is, you know, the idea of enabling people to live an ordinary life in circumstances where previously they would have just been ruled out of that because they wouldn’t have had the the capabilities to do it.
I have colleagues who think that they’re going to be able to recognize the onset of dementia just from the way that people use their smartphone. So, for example, one of the symptoms of dementia will be that simple cognitive tasks like finding somebody in a contact list on your phone, that you get confused and it takes you longer to do that. So, spotting changes in people’s behaviour through AI is something which sounds feasible. Now, I emphasize the technology isn’t there yet, but there’s no reason why it couldn’t be.
Acker: The medical advances that are happening today we think are just the tip of the iceberg of what will be coming in the future. The amount of information and processing power is compounding, and the amount of information that we’re getting about, for example, the underlying genetic causes of disease, these are compounding at such a high rate that we think they’re going to lead to significant breakthroughs in the future. In fact, many have called the upcoming century the Century of Biology, and we couldn’t agree more with that assessment.
de Lagarde: I’m confident that this is just the beginning of this incredible medical technology progress that we’re making with artificial intelligence. I can see that this technology can be applied to a much vaster range of not just prosthetics but support for increased mobility, which will be interesting for an aging population to remain mobile for as long as they can.
Acker: The opportunities for innovation remain enormous. There are so many high, unmet medical needs. If we think about cancer, heart disease, diabetes, those suffering from accidents and needing replacement of limbs. And we see medicine and healthcare changing dramatically with these applications of technology, and we think that’s going to create enormous opportunities for investors in the years to come.
Related insights
These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
The information in this article does not qualify as an investment recommendation.
There is no guarantee that past trends will continue, or forecasts will be realised.
Marketing Communication.
Important information
Please read the following important information regarding funds related to this article.
- Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
- When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
- Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
- The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets.
- The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
Specific risks
- Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
- When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
- Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
- The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
Specific risks
7 minute watch
Key takeaways:
- Although artificial intelligence (AI) will likely have a wide range of applications, the technology’s impact on healthcare could be felt globally.
- AI-enabled prosthetic limbs, for example, can now mimic fine motor functions, as explained by Sarah de Lagarde, who has used one since losing her right arm in a severe train accident.
- Such innovation is accelerating throughout the healthcare sector and creating a multitude of opportunities for both patients and investors.